Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Sage Therapeutics

16/06/2025 12:06

June 16 (Reuters) - Drugmaker Supernus Pharmaceuticals SUPN.O said on Monday it will acquire Sage Therapeutics SAGE.O, which makes treatments for neurological conditions, in a deal worth up to $795 million.

Supernus has offered $8.50 in cash for each of Sage's share and up to $3.50 per share in cash if certain milestones are achieved.

Shares of Sage Therapeutics were halted in premarket trading.

 (Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)

 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))